Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR β signalling

Cancer Letters

Volumn 273, Issue 1, 2009, Pages 70-79

  Weigel, Marion T ^a   Meinhold Heerlein, Ivo ^a   Bauerschlag, Dirk O ^a   Schem, Christian ^a   Bauer, Maret ^a   Jonat, Walter ^a   Maass, Nicolai ^a   Mundhenke, Christoph ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Akt; Breast cancer; Imatinib mesylate; PDGFR; Targeted therapy

Indexed keywords

IMATINIB; MESSENGER RNA; NAVELBINE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B BETA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; VINBLASTINE;

EID: 56349117935     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.07.040     Document Type: Article

References (43)

1. Dickson R.B., and Lippman M.E. Growth factors in breast cancer. Endocr. Rev. 16 (1995) 559-589
2. Hines S.J., Litz J.S., and Krystal G.W. Coexpression of c-kit and stem cell factor in breast cancer results in enhanced sensitivity to members of the EGF family of growth factors. Breast Cancer Res. Treat. 58 (1999) 1-10
3. Ulivi P., Zoli W., Medri L., Amadori D., Saragoni L., Barbanti F., Calistri D., and Silvestrini R. c-kit and SCF expression in normal and tumor breast tissue. Breast Cancer Res. Treat. 83 (2004) 33-42
4. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.J., and Lydon N.B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56 (1996) 100-104
5. Druker B.J. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med. 8 (2002) S14-18
6. Carroll M., Ohno-Jones S., Tamura S., Buchdunger E., Zimmermann J., Lydon N.B., Gilliland D.G., and Druker B.J. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90 (1997) 4947-4952
7. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., and Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 (2000) 925-932
8. Pietras K., Sjoblom T., Rubin K., Heldin C.H., and Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 3 (2003) 439-443
9. Schiffer C.A. Signal transduction inhibition: changing paradigms in cancer care. Semin. Oncol. 28 (2001) 34-39
10. Seymour L., Dajee D., and Bezwoda W.R. Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res. Treat. 26 (1993) 247-252
11. Mundhenke C., Weigel M.T., Sturner K.H., Roesel F., Meinhold-Heerlein I., Bauerschlag D.O., Schem C., Hilpert F., Jonat W., and Maass N. Novel treatment of ovarian cancer cell lines with imatinib mesylate combined with paclitaxel and carboplatin leads to receptor-mediated antiproliferative effects. J. Cancer Res. Clin. Oncol. (2008)
12. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., and Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2 (1996) 561-566
13. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., and Lydon N.B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295 (2000) 139-145
14. Sjoblom T., Shimizu A., O'Brien K.P., Pietras K., Dal Cin P., Buchdunger E., Dumanski J.P., Ostman A., and Heldin C.H. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 61 (2001) 5778-5783
15. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., Silberman S., Capdeville R., Dimitrijevic S., Druker B., and Demetri G.D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344 (2001) 1052-1056
16. Buchdunger E., O'Reilly T., and Wood J. Pharmacology of imatinib (STI571). Eur. J. Cancer 38 5 (2002) S28-36
17. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B.J., Corless C., Fletcher C.D., and Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347 (2002) 472-480
18. Beppu K., Jaboine J., Merchant M.S., Mackall C.L., and Thiele C.J. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J. Natl. Cancer Inst. 96 (2004) 46-55
19. Fang G., Kim C.N., Perkins C.L., Ramadevi N., Winton E., Wittmann S., and Bhalla K.N. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 96 (2000) 2246-2253
20. Lev D.C., Kim S.J., Onn A., Stone V., Nam D.H., Yazici S., Fidler I.J., and Price J.E. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin. Cancer Res. 11 (2005) 306-314
21. Brama M., Basciani S., Cherubini S., Mariani S., Migliaccio S., Arizzi M., Rosano G., Spera G., and Gnessi L. Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment. Endocr. Relat. Cancer 14 (2007) 61-72
22. Matei D., Chang D.D., and Jeng M.H. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin. Cancer Res. 10 (2004) 681-690
23. Remmele W., and Stegner H.E. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathology 8 (1987) 138-140
24. Bhardwaj B., Klassen J., Cossette N., Sterns E., Tuck A., Deeley R., Sengupta S., and Elliott B. Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma. Clin. Cancer Res. 2 (1996) 773-782
25. de Jong J.S., van Diest P.J., van der Valk P., and Baak J.P. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J. Pathol. 184 (1998) 53-57
26. Rocha A., Azevedo I., and Soares R. Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects. J. Cell. Biochem. (2007)
27. Nishida K., Tsukamoto T., Uchida K., Takahashi T., Takahashi T., and Ueda R. Introduction of the c-kit gene leads to growth suppression of a breast cancer cell line, MCF-7. Anti-cancer Res. 16 (1996) 3397-3402
28. Uziel O., Fenig E., Nordenberg J., Beery E., Reshef H., Sandbank J., Birenbaum M., Bakhanashvili M., Yerushalmi R., Luria D., and Lahav M. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br. J. Cancer 92 (2005) 1881-1891
29. Bronzert D.A., Pantazis P., Antoniades H.N., Kasid A., Davidson N., Dickson R.B., and Lippman M.E. Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc. Natl. Acad. Sci. USA 84 (1987) 5763-5767
30. Apte S.M., Fan D., Killion J.J., and Fidler I.J. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin. Cancer Res. 10 (2004) 897-908
31. Guha A., Dashner K., Black P.M., Wagner J.A., and Stiles C.D. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int. J. Cancer 60 (1995) 168-173
32. Roussidis A.E., Theocharis A.D., Tzanakakis G.N., and Karamanos N.K. The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer. Curr. Med. Chem. 14 (2007) 735-743
33. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., and Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 (2001) 1031-1037
34. Yerushalmi R., Nordenberg J., Beery E., Uziel O., Lahav M., Luria D., and Fenig E. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro. Exp. Oncol. 29 (2007) 126-131
35. McGary E.C., Weber K., Mills L., Doucet M., Lewis V., Lev D.C., Fidler I.J., and Bar-Eli M. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin. Cancer Res. 8 (2002) 3584-3591
36. Greene L.M., Kelly L., Onnis V., Campiani G., Lawler M., Williams D.C., and Zisterer D.M. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells. J. Pharmacol. Exp. Ther. 321 (2007) 288-297
37. Yoon S.Y., Tefferi A., and Li C.Y. Cellular distribution of platelet-derived growth factor, transforming growth factor-beta, basic fibroblast growth factor, and their receptors in normal bone marrow. Acta Haematol. 104 (2000) 151-157
38. Thyberg J. The microtubular cytoskeleton and the initiation of DNA synthesis. Exp. Cell Res. 155 (1984) 1-8
39. Langley R.R., Fan D., Tsan R.Z., Rebhun R., He J., Kim S.J., and Fidler I.J. Activation of the platelet-derived growth factor-receptor enhances survival of murine bone endothelial cells. Cancer Res. 64 (2004) 3727-3730
40. Jechlinger M., Sommer A., Moriggl R., Seither P., Kraut N., Capodiecci P., Donovan M., Cordon-Cardo C., Beug H., and Grunert S. Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Invest. 116 (2006) 1561-1570
41. Modi S., Seidman A.D., Dickler M., Moasser M., D'Andrea G., Moynahan M.E., Menell J., Panageas K.S., Tan L.K., Norton L., and Hudis C.A. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res. Treat. 90 (2005) 157-163
42. Cristofanilli M., Morandi P., Krishnamurthy S., Reuben J.M., Lee B.N., Francis D., Booser D.J., Green M.C., Arun B.K., Pusztai L., Lopez A., Islam R., Valero V., and Hortobagyi G.N. Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR-{beta}: clinical activity and biological correlations. Ann. Oncol. (2008)
43. Vlahovic G., Rabbani Z.N., Herndon II J.E., Dewhirst M.W., and Vujaskovic Z. Treatment with imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br. J. Cancer 95 (2006) 1013-1019